Stay updated on PI3K/Akt Suppression vs MK-3475 in Glioblastoma Clinical Trial

Sign up to get notified when there's something new on the PI3K/Akt Suppression vs MK-3475 in Glioblastoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the PI3K/Akt Suppression vs MK-3475 in Glioblastoma Clinical Trial page

  1. Check
    5 days ago
    No Change Detected
  2. Check
    12 days ago
    Change Detected
    Summary
    The website has been updated from version 2.10.2 to 2.10.3, indicating a new release.
    Difference
    0.1%
    Check dated 2024-09-04T03:54:57.000Z thumbnail image
  3. Check
    19 days ago
    No Change Detected
  4. Check
    26 days ago
    No Change Detected
  5. Check
    34 days ago
    Change Detected
    Summary
    The website has been updated from version 2.10.0 to 2.10.2, indicating new features or improvements.
    Difference
    0.1%
    Check dated 2024-08-13T22:16:24.000Z thumbnail image
  6. Check
    55 days ago
    Change Detected
    Summary
    The study has expanded to include 13 locations, and the revision has been updated from v2.9.7 to v2.10.0.
    Difference
    0.4%
    Check dated 2024-07-23T14:24:43.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    The website has been updated to Revision v2.9.7 from v2.9.6.
    Difference
    0.1%
    Check dated 2024-07-16T07:43:07.000Z thumbnail image
  8. Check
    76 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent change in the webpage content related to the study evaluating the effectiveness of treatment for Glioblastoma / Gliosarcoma through the suppression of the PI3K/Akt pathway compared with MK-3475 (Pembrolizumab).
    Difference
    0.1%
    Check dated 2024-07-02T13:34:44.000Z thumbnail image
  9. Check
    81 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.3 to v2.9.5, indicating a recent change in the webpage content related to the study evaluating the effectiveness of treatment for Glioblastoma / Gliosarcoma through the suppression of the PI3K/Akt pathway compared with MK-3475 (Pembrolizumab).
    Difference
    0.1%
    Check dated 2024-06-27T09:47:26.000Z thumbnail image

Stay in the know with updates to PI3K/Akt Suppression vs MK-3475 in Glioblastoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the PI3K/Akt Suppression vs MK-3475 in Glioblastoma Clinical Trial page.